SUZ12 and neoplasm: Notably, recent studies have linked the inactivation of Polycomb Repressive Complex 2 (PRC2), which contains SUZ12 as a core subunit, to enhanced anti-tumor cytotoxicity of DAC through retroelement reactivation and the associated inflammatory response (Chomiak et al, 2024; Kim et al, 2023; Patel et al, 2022).